07:00 , May 30, 2011 |  BC Week In Review  |  Company News

Varian Medical Systems, Cancer Research UK, The University of Auckland deal

The university granted Varian's Centella Therapeutics Inc. subsidiary exclusive, worldwide rights to CEN-209. Centella then partnered with Cancer Research to develop the hypoxia-activated cytotoxic prodrug as an adjunct to radiotherapy and chemotherapy to treat...